导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.72% | 1564/4766 |
| 近一周 | -0.98% | 1462/5456 |
| 近一月 | -3.50% | 2562/5412 |
| 近一季 | -9.31% | 3536/5222 |
| 近半年 | -4.92% | 2955/4911 |
| 近一年 | 7.96% | 1395/4391 |
| 近两年 | 73.74% | 949/2953 |
| 近三年 | 39.41% | 782/2252 |
| 成立以来 | 89.42% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.01% 1099/4961 |
18.66% 1355/5312 |
- - |
- - |
| 2025 | 31.56% 1231/4813 |
2.71% 1284/3635 |
2.08% 1888/4076 |
24.21% 1490/4524 |
1.02% 1587/4813 |
| 2024 | 7.10% 1692/3463 |
-2.74% 1421/2808 |
-4.99% 1612/3014 |
15.47% 1707/3129 |
0.37% 1220/3463 |
| 2023 | -4.51% 681/2656 |
7.63% 545/2280 |
-3.46% 801/2385 |
-3.83% 999/2515 |
-4.43% 1032/2655 |
| 2022 | -16.63% 499/2207 |
-12.97% 677/1919 |
3.26% 1184/2016 |
-9.71% 300/2113 |
2.74% 848/2208 |
| 2021 | 21.78% 158/1822 |
-0.46% 368/1255 |
11.38% 379/1330 |
5.73% 258/1466 |
3.89% 384/1822 |
| 2020 | - - |
- - |
18.25% 348/1067 |
11.39% 456/1164 |
4.06% 874/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 鹏华中证500ETF联接C VS. 长安沪深300非周期A(740101) |